News about Global Pharma

Akeso's Ivonescimab Wins 4th Breakthrough Therapy Nod in China for TNBC

Akeso has secured its fourth Breakthrough Therapy Designation (BTD) in China for Ivonescimab, targeting first-line treatment of triple-negative breast cancer (TNBC). The ongoing Phase III HARMONi-BC1 trial is assessing its safety and efficacy in this hard-to-treat cancer type.

Global Pharma | 03/11/2025 | By Dineshwori |  212

EU Approves KEYTRUDA for PD-L1+ Resectable Head and Neck Cancer

KEYTRUDA monotherapy has been approved for use as a neoadjuvant treatment, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and continued thereafter as maintenance monotherapy.

Global Pharma | 30/10/2025 | By Dineshwori |  214

GSK Raises 2025 Outlook as Cancer and HIV Drug Sales Surge

Despite a significant fall in USA sales of its shingles vaccine, Shingrix, GSK shares climbed to their highest level since May 2024, rising as much as 4.3 per cent. The stock has already advanced about 25 per cent this year.

Global Pharma | 30/10/2025 | By Darshana |  319

Japan's Cambridge Isotope Laboratories Partners with Chemtatva Chiral Solutions to Launch New Entity in Hyderabad

Cambridge Isotope Laboratories (CIL), a subsidiary of Japan’s Otsuka Pharmaceutical, has signed a Memorandum of Understanding (MoU) with Hyderabad-based Chemtatva Chiral Solutions (CCS) to establish a new entity — Cambridge Isotope Laboratories Pvt. Ltd. — in Hyderabad, India.

Global Pharma | 29/10/2025 | By Dineshwori |  406

GHIT Fund Announces USD 11.6 Million to Boost R&D for TB, Leishmaniasis and Malaria

The Global Health Innovative Technology (GHIT) Fund, a Japan-based international public-private partnership (PPP), has announced a total investment of approximately USD 11.6 million to support four new research and development (R&D) projects targeting tuberculosis (TB), neglected tropical diseases (NTDs) and malaria.

Global Pharma | 29/10/2025 | By Dineshwori |  208

KP Group and Fabtech Group Partner to Build Green Infrastructure for Global Life Sciences Projects

Under the partnership, all projects executed by Fabtech Group—including conventional and stick-built—will be powered by clean, renewable energy supplied by KP Group.

Global Pharma | 28/10/2025 | By Dineshwori |  206

Lupin Expands US Footprint with New Corporate Offices in Bridgewater, New Jersey

Lupin has inaugurated its new corporate offices at 100 Somerset Corporate Blvd, Bridgewater, New Jersey, expanding its presence in the state where it already operates manufacturing and research facilities.

Global Pharma | 28/10/2025 | By Dineshwori |  297

Akums Expands Global Footprint with New Pharmaceutical Facility in Zambia

Akums Drugs & Pharmaceuticals has held the groundbreaking ceremony of its first overseas manufacturing facility in Zambia, marking a major milestone in its global expansion journey.

Global Pharma | 28/10/2025 | By Dineshwori |  261

Health Canada Grants Authorisation for Leqembi (Lecanemab)

BioArctic has the right to commercialise Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialisation in the region.

Global Pharma | 28/10/2025 | By Dineshwori |  227

GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC

GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.

Global Pharma | 27/10/2025 | By Dineshwori |  314